Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Apigenin

Apigenin (Chamomile Extract) · also known as Chamomile extract, Apigenin, Apigenin

In in-vitro and mouse experiments, apigenin can inhibit CD38 and raise liver NAD+, but its target occupancy in humans is unclear. Its sedative effect may involve GABAergic pathways, though receptor-level evidence is inconsistent and a sedative effect in humans has not been established.

Typical dose: 50–200 mg/day, taken in the evening or 30–60 minutes before bed. This dose has not been established as effective for pure apigenin to improve sleep or inhibit CD38 in humans, and chamomile extract cannot be treated as equivalent to the same amount of pure apigenin.
Absorption and forms: Pure apigenin is fairly fat-soluble. Taking it with a main meal that contains fat, or 1 hour before bed with a little healthy fat (such as nuts or triglycerides), is recommended to promote lymphatic absorption.

Clinical uses and human evidence

Anxiety and stress

BeneficialGrade C · Preliminary evidence
Studies (1)
  1. Amsterdam 2009 · J Clin Psychopharmacol · RCT · n=57 — A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder

Sleep quality

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Zick 2011 · BMC Complement Altern Med · RCT · n=34 — Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study

Mechanisms of action

GABA and glutamate balance (inhibitory and excitatory tone)

★★★☆☆Mechanism evidence: grade CSecondary target

Animal studies suggest apigenin’s sedative effect may involve GABAergic pathways. However, a benzodiazepine-site antagonist blocked only part of the sedative effects and receptor-level results are inconsistent, so its specificity for that site cannot yet be determined. A sedative effect in humans has not been established, and this cannot be taken to mean that ataxia will not occur.

References (2)
  1. 2015 · Mouse and receptor expression experiments: flumazenil blocked some sedative effects, but apigenin did not enhance the measured GABA-A receptor currents
  2. 2000 · Rat study: motor suppression was not blocked by a benzodiazepine-site antagonist

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★☆☆☆Mechanism evidence: grade CSecondary target

Animal studies support the idea that apigenin suppresses NF-κB-related SASP pro-inflammatory signaling. Its pathway effects in human tissue after oral dosing are unclear, and this mechanism currently rests mainly on cell and animal work.

References (1)
  1. Zhang 2025 · Cell and mouse studies, plus the animal studies they cite: support apigenin’s suppression of NF-κB-related SASP

CD38 ectonucleotidase inhibition (a brake on NAD+ consumption)

★☆☆☆☆Mechanism evidence: grade DPrimary target

In enzyme assays, apigenin inhibited CD38 with an IC50 of about 10.3 μmol/L, and liver NAD+ rose in treated mice. However, this in-vitro inhibitory concentration is far above the plasma levels measured in human dietary studies, and whether 50–200 mg of pure apigenin can reach an effective free exposure in humans has not been confirmed.

References (2)
  1. Escande 2013 · Enzyme assay and mouse study: apigenin inhibited CD38 with an in-vitro IC50 of about 10.3 μmol/L, and liver NAD+ rose in treated mice
  2. 2006 · 11-person pharmacokinetic study: after eating apigenin-rich parsley, peak plasma concentration was about 0.127 μmol/L (a different form from pure apigenin)

Apoptosis-driven clearance of senescent cells (senolytic activity)

★☆☆☆☆Mechanism evidence: grade DSecondary target

In cell and mouse studies, apigenin reduced the senescence-associated secretory phenotype (SASP) and lowered the output of pro-inflammatory cytokines. But suppressing the secretory phenotype is not the same as clearing senescent cells, and there is currently no reliable evidence that apigenin selectively clears senescent cells.

References (1)
  1. Zhang 2025 · Cell and mouse study: apigenin reduced the senescence-associated secretory phenotype, and screening did not show selective clearance of senescent cells

Safety and drug interactions

When combining it with central nervous system sedatives such as diazepam, watch for additive CNS depression, although this interaction has not been well studied. High doses may compete for binding to estrogen receptors.

Additive sedation

Has a mild sedative effect. Each of these has some sedative or sleep-promoting effect. Taken together, they may cause daytime drowsiness and slower reactions. Do not drive or work at heights after taking them.

Open in the interactive app ›